Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action

Molecular Partners has presented new data on its lead Radio-DARPin MP0712, targeting DLL3, at the Targeted Radiopharmaceuticals Summit Europe. The data includes first human images and mechanism of action, showing specific uptake in tumors and limited exposure in healthy organs. Phase 1 IND for MP0712 has been filed, with clinical trial initiation expected before the end of 2025, and initial data expected in 2026. The company will host a conference call today to discuss the findings.